Vimta Labs Share Price
Sector: Biotechnology & Drugs
438.00 -16.25 (-3.58%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
435.60
Today’s High
458.90
52 Week Low
233.25
52 Week High
591.50
438.20 -14.80 (-3.27%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
435.30
Today’s High
458.85
52 Week Low
236.03
52 Week High
589.00
Key Metrics
- Market Cap (In Cr) 1954.73
- Beta 0.21
- Div. Yield (%) 0.44
- P/B 5.32
- TTM P/E 33.45
- Peg Ratio 1.75
- Sector P/E 0
- D/E 0
- Open Price 454.2
- Prev Close 454.25
Vimta Labs Analysis
Price Analysis
-
1 Week-6.16%
-
3 Months-10.25%
-
6 Month-8.62%
-
YTD-8.87%
-
1 Year85.98%
Risk Meter
- 69% Low risk
- 69% Moderate risk
- 69% Balanced Risk
- 69% High risk
- 69% Extreme risk
Vimta Labs News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 21 Mar 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends seven shares to buy
1 min read . 19 Mar 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 17 Feb 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
2 min read . 13 Feb 2025Vimta Labs Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 344.17
- Selling/ General/ Admin Expenses Total
- 149.16
- Depreciation/ Amortization
- 35.29
- Other Operating Expenses Total
- 1.43
- Total Operating Expense
- 257.32
- Operating Income
- 86.85
- Net Income Before Taxes
- 89
- Net Income
- 67.34
- Diluted Normalized EPS
- 14.79
- Period
- 2025
- Total Assets
- 466.53
- Total Liabilities
- 87.68
- Total Equity
- 378.85
- Tangible Book Valueper Share Common Eq
- 83.75
- Period
- 2025
- Cashfrom Operating Activities
- 94.61
- Cashfrom Investing Activities
- -75.54
- Cashfrom Financing Activities
- -16.68
- Net Changein Cash
- 2.4
- Period
- 2024
- Total Revenue
- 288.59
- Selling/ General/ Admin Expenses Total
- 135.68
- Depreciation/ Amortization
- 33.14
- Other Operating Expenses Total
- 1.22
- Total Operating Expense
- 227.7
- Operating Income
- 60.9
- Net Income Before Taxes
- 62.5
- Net Income
- 41.01
- Diluted Normalized EPS
- 10.76
- Period
- 2024
- Total Assets
- 394.47
- Total Liabilities
- 80.35
- Total Equity
- 314.12
- Tangible Book Valueper Share Common Eq
- 68.79
- Period
- 2024
- Cashfrom Operating Activities
- 60.89
- Cashfrom Investing Activities
- -76.05
- Cashfrom Financing Activities
- -1.9
- Net Changein Cash
- -17.06
- Period
- 2023
- Total Revenue
- 318.19
- Selling/ General/ Admin Expenses Total
- 149.14
- Depreciation/ Amortization
- 30.71
- Other Operating Expenses Total
- 0.29
- Total Operating Expense
- 253.99
- Operating Income
- 64.2
- Net Income Before Taxes
- 65
- Net Income
- 48.17
- Diluted Normalized EPS
- 10.64
- Period
- 2023
- Total Assets
- 362.33
- Total Liabilities
- 80.54
- Total Equity
- 281.79
- Tangible Book Valueper Share Common Eq
- 59.65
- Period
- 2023
- Cashfrom Operating Activities
- 87.94
- Cashfrom Investing Activities
- -57.26
- Cashfrom Financing Activities
- -10.98
- Net Changein Cash
- 19.7
- Period
- 2022
- Total Revenue
- 278.28
- Selling/ General/ Admin Expenses Total
- 118.43
- Depreciation/ Amortization
- 23.33
- Other Operating Expenses Total
- 0.14
- Total Operating Expense
- 222.32
- Operating Income
- 55.96
- Net Income Before Taxes
- 55.69
- Net Income
- 41.33
- Diluted Normalized EPS
- 9.35
- Period
- 2022
- Total Assets
- 307.2
- Total Liabilities
- 73.21
- Total Equity
- 233.98
- Tangible Book Valueper Share Common Eq
- 48.64
- Period
- 2022
- Cashfrom Operating Activities
- 59.07
- Cashfrom Investing Activities
- -37.85
- Cashfrom Financing Activities
- -16.61
- Net Changein Cash
- 4.61
- Period
- 2021
- Total Revenue
- 210.68
- Selling/ General/ Admin Expenses Total
- 95.99
- Depreciation/ Amortization
- 23.08
- Other Operating Expenses Total
- 0.17
- Total Operating Expense
- 180.35
- Operating Income
- 30.33
- Net Income Before Taxes
- 28.54
- Net Income
- 21.41
- Diluted Normalized EPS
- 4.84
- Period
- 2021
- Total Assets
- 274.36
- Total Liabilities
- 79.98
- Total Equity
- 194.38
- Tangible Book Valueper Share Common Eq
- 42.7
- Period
- 2021
- Cashfrom Operating Activities
- 37.18
- Cashfrom Investing Activities
- -31.92
- Cashfrom Financing Activities
- -4.57
- Net Changein Cash
- 0.69
- Period
- 2020
- Total Revenue
- 180.71
- Selling/ General/ Admin Expenses Total
- 96.74
- Depreciation/ Amortization
- 20.93
- Other Operating Expenses Total
- 0.28
- Total Operating Expense
- 171.7
- Operating Income
- 9.02
- Net Income Before Taxes
- 8.27
- Net Income
- 6.85
- Diluted Normalized EPS
- 1.52
- Period
- 2020
- Total Assets
- 245.69
- Total Liabilities
- 72.82
- Total Equity
- 172.88
- Tangible Book Valueper Share Common Eq
- 37.84
- Period
- 2020
- Cashfrom Operating Activities
- 24.35
- Cashfrom Investing Activities
- -20.84
- Cashfrom Financing Activities
- -0.67
- Net Changein Cash
- 2.84
- Period
- 2025-03-31
- Total Revenue
- 94.44
- Selling/ General/ Admin Expenses Total
- 30.45
- Depreciation/ Amortization
- 9.21
- Other Operating Expenses Total
- 12.78
- Total Operating Expense
- 70.62
- Operating Income
- 23.83
- Net Income Before Taxes
- 25.03
- Net Income
- 18.32
- Diluted Normalized EPS
- 4.03
- Period
- 2025-03-31
- Total Assets
- 466.53
- Total Liabilities
- 87.68
- Total Equity
- 378.85
- Tangible Book Valueper Share Common Eq
- 83.75
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 99.64
- Cashfrom Investing Activities
- -80.05
- Cashfrom Financing Activities
- -16.68
- Net Changein Cash
- 2.4
- Period
- 2024-12-31
- Total Revenue
- 89.92
- Selling/ General/ Admin Expenses Total
- 23.37
- Depreciation/ Amortization
- 9.81
- Other Operating Expenses Total
- 12.84
- Total Operating Expense
- 66.65
- Operating Income
- 23.28
- Net Income Before Taxes
- 23.92
- Net Income
- 21.49
- Diluted Normalized EPS
- 3.89
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 84.74
- Selling/ General/ Admin Expenses Total
- 23.94
- Depreciation/ Amortization
- 8.29
- Other Operating Expenses Total
- 12.55
- Total Operating Expense
- 63.13
- Operating Income
- 21.61
- Net Income Before Taxes
- 21.89
- Net Income
- 15.25
- Diluted Normalized EPS
- 3.77
- Period
- 2024-09-30
- Total Assets
- 440.41
- Total Liabilities
- 97.67
- Total Equity
- 342.74
- Tangible Book Valueper Share Common Eq
- 74.33
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 48.83
- Cashfrom Investing Activities
- -35.26
- Cashfrom Financing Activities
- -12.75
- Net Changein Cash
- 0.83
- Period
- 2024-06-30
- Total Revenue
- 74.88
- Selling/ General/ Admin Expenses Total
- 22.45
- Depreciation/ Amortization
- 7.98
- Other Operating Expenses Total
- 12.21
- Total Operating Expense
- 56.93
- Operating Income
- 17.95
- Net Income Before Taxes
- 18.17
- Net Income
- 12.28
- Diluted Normalized EPS
- 3.08
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 72.73
- Selling/ General/ Admin Expenses Total
- 25.08
- Depreciation/ Amortization
- 7.84
- Other Operating Expenses Total
- 8.36
- Total Operating Expense
- 54.65
- Operating Income
- 18.08
- Net Income Before Taxes
- 17.94
- Net Income
- 12.35
- Diluted Normalized EPS
- 3.02
- Period
- 2024-03-31
- Total Assets
- 394.47
- Total Liabilities
- 80.35
- Total Equity
- 314.12
- Tangible Book Valueper Share Common Eq
- 68.79
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 60.89
- Cashfrom Investing Activities
- -76.05
- Cashfrom Financing Activities
- -1.9
- Net Changein Cash
- -17.06
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Vimta Labs Technical
Moving Average
SMA
- 5 Day472.25
- 10 Day483.46
- 20 Day481.67
- 50 Day495.91
- 100 Day490.73
- 300 Day430.49
Vimta Labs Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sms Pharmaceuticals
- 248.55
- 1.8
- 0.73
- 398
- 175
- 2199.77
- Amrutanjan Health Care
- 735.35
- 7.5
- 1.03
- 861.4
- 548.05
- 2140.7
- Vimta Labs
- 438
- -16.25
- -3.58
- 591.5
- 233.25
- 1954.73
- Windlas Biotech
- 891.1
- -2.9
- -0.32
- 1197
- 656.25
- 1863.15
- Syncom Formulations (india)
- 19.26
- 0.02
- 0.1
- 27.94
- 12.31
- 1798.4
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sms Pharmaceuticals
- 29.3
- 3.31
- 9.98
- 8.05
- Amrutanjan Health Care
- 41.65
- 6.48
- 20.26
- 13.26
- Vimta Labs
- 31.61
- 5.49
- 17.42
- 15.73
- Windlas Biotech
- 31.41
- 3.75
- 11.96
- 7.7
- Syncom Formulations (india)
- 34.09
- 5.34
- 12
- 10.15
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-Jun-25
- Others
- 28-Apr-25
- Audited Results, Dividend & Bonus issue
- 24-Jan-25
- Quarterly Results
- 08-Nov-24
- Quarterly Results
- 17-Jul-24
- Quarterly Results
- 18-May-24
- Audited Results & Final Dividend
- 30-Mar-24
- Amalgamation
- 31-Jan-24
- Quarterly Results
- 30-Oct-23
- Quarterly Results
- 28-Jul-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 06-Jun-25
- 15-May-25
- AGM
- 18-Jul-24
- 21-May-24
- AGM
- 28-Mar-24
- 23-Feb-24
- POM
- 28-Jun-23
- 01-Jun-23
- AGM
- 05-Jul-21
- 14-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 28-Apr-25
- 30-May-25
- 30-May-25
- 2
- 21-May-24
- -
- 11-Jul-24
- 2
- 03-May-23
- -
- 21-Jun-23
- 2
- 12-May-22
- 18-Jun-22
- 16-Jun-22
- 2
- 14-May-21
- 28-Jun-21
- 25-Jun-21
- 2
- Announced on
- Record Date
- Ex-Bonus
- Description
- 28-Apr-25
- 13-Jun-25
- 13-Jun-25
- Bonus issue of equity shares in the ratio of 1:1 of Rs. 2/-.

